The UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the use of Beyonttra (acoramidis) in the UK for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).  ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure.  Beyonttra is an orally […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!